News
Video
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Author(s):
Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).
Latest CME
View All
Video
Addressing Unmet Needs in HER2+ Metastatic BTC
Apr 18th 2025 - Apr 19th 2026
online-activity
Video
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Apr 17th 2025 - May 23rd 2025
online-activity
Video
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Apr 17th 2025 - May 23rd 2025
online-activity
Related Content
.png?fit=crop&auto=format)
.jpg?fit=crop&auto=format)
